Full-Time

Manufacturing Technician I

Buffer Prep, M-F, 7am-3:30pm

Updated on 9/3/2026

Genezen

Genezen

201-500 employees

Viral-vector and cell-therapy CDMO provider

Compensation Overview

$27 - $33/hr

No H1B Sponsorship

Lexington, MA, USA

In Person

Bachelor's

Category
Manufacturing & Production Operations (1)
Required Skills
ERP
GMP
FDA Regulations

Get referred to Genezen

See people who can refer or advise you

Requirements
  • The role requires a high school, associate, or bachelor's degree, preferably in a Life Sciences or Engineering field.
  • The role requires 0-2 years of prior manufacturing experience, preferably in a comparable position and preferentially in an industrial organization.
  • The role requires hands-on experience writing and reviewing documentation.
  • The role requires experience in biomanufacturing unit operations, including upstream processing and/or downstream processing.
  • The role requires the ability to lift up to 40 pounds.
  • The role requires working knowledge of and adherence to standard operating procedures, Good Documentation Practices, and applicable regulatory requirements.
  • The role requires commitment to maintaining compliance with internal and regulatory policies, processes, and procedures, including European Medicines Agency and Food and Drug Administration requirements.
  • The role requires strong written, verbal, and interpersonal communication skills to communicate effectively across departments.
  • The role requires the ability to apply technical expertise and experience to achieve assigned objectives.
  • The role requires attention to detail, organizational skills, and a structured, process-driven approach.
  • The role requires the ability to prioritize tasks and manage multiple responsibilities.
  • The role requires sound judgment and initiative in a rapidly changing manufacturing and development environment.
  • A criminal background check is required.
  • The employee must be eligible to work in the United States.
Responsibilities
  • Execute routine and non-routine production activities according to the manufacturing schedule.
  • Follow current Good Manufacturing Practice requirements, standard operating procedures, batch records, and solution preparation records.
  • Use the Enterprise Resource Planning system to execute transactions accurately and in real time.
  • Demonstrate and apply aseptic processing techniques.
  • Operate in production areas including pre-culture, upstream processing, downstream processing, buffer preparation, and fill-finish.
  • Perform troubleshooting activities within established procedures.
  • Participate in shift handoffs and communicate critical production information.
  • Support off-shift, overtime, and holiday production activities as required.
  • Complete manufacturing documentation accurately and in real time following Good Documentation Practices principles.
  • Review batch records, solution records, logbooks, and forms for completeness and accuracy.
  • Maintain training compliance and keep required qualifications current.
  • Identify and escalate potential safety concerns.
  • Perform routine equipment cleaning and standardization activities.
  • Support product changeovers and manufacturing readiness activities.
  • Assist with equipment, process qualification, and validation efforts.
  • Conduct facility walkthroughs and maintain manufacturing areas in an inspection-ready state.
  • Coordinate equipment and facility issues with Senior and Lead Technicians.
  • Maintain an individual development plan and build technical expertise.
  • Complete annual self-assessments and participate in performance development discussions.
Desired Qualifications
  • Experience in a comparable manufacturing position, particularly in an industrial organization.
  • Flexibility to adapt as the work schedule changes based on business needs.

Genezen is a contract development and manufacturing organization specializing in gene and cell therapies, focusing on viral vectors, transduced cells, and related analytics. It offers end-to-end, fee-for-service development and cGMP manufacturing from early development to clinical-grade vectors for trials. It differentiates itself by providing a focused, global CDMO service that covers the full pipeline for viral vectors and cell therapies under one partner. Its goal is to help clients advance gene and cell therapy programs toward clinical trials and potential treatments through reliable development, manufacturing, and testing support.

Company Size

201-500

Company Stage

Growth Equity (Venture Capital)

Total Funding

$18.5M

Headquarters

Iowa City, Iowa

Founded

2014

Get referred to Genezen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 Raiden partnership pushes UBA5 from four years R&D into clinic.
  • August 2026 4basebio collaboration cuts DNA input, speeding AAV development and lowering client costs.
  • January 2026 Atsena partnership expands commercial manufacturing, proving Genezen wins late-stage programs.

What critics are saying

  • April 2026 CSL terminated Genezen's HEMGENIX supply obligations, removing a marquee revenue anchor.
  • Gene therapy funding remains fragile; if 2026 startups stall, Lexington capacity sits underfilled.
  • One facility shock at Lexington or Indianapolis would cripple deliveries and threaten Genezen's viability.

What makes Genezen unique

  • Genezen owns Lexington's licensed commercial viral-vector site and Indianapolis clinical manufacturing.
  • It spans AAV, lentiviral, retroviral, and oncolytic virus workflows under one CDMO.
  • 2024 uniQure transition brought experienced staff, regulatory licenses, and commercial supply credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Company Match

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

15%
WOWK-TV
Aug 26th, 2026
4basebio and Genezen enter into strategic collaboration to advance synthetic, cell-free DNA platforms for next-generation viral vector manufacturing.

4basebio and Genezen enter into strategic collaboration to advance synthetic, cell-free DNA platforms for next-generation viral vector manufacturing. Aug 26, 2026, 2:15 AM ET Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and commercial manufacturing. CAMBRIDGE, United Kingdom and INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ - 4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced, cell-free DNA for new genetic medicines, and Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO), today announced an expanded, non-exclusive collaboration providing drug developers access to 4basebio's Research Use Only, High-Quality, and GMP-grade hpDNA(R) development and clinical programs. Through the collaboration, Genezen will offer access to 4basebio's synthetic DNA developed specifically for viral vector applications, creating a more streamlined path for cell and gene therapy developers to advance programs toward the clinic. 4basebio's enzymatic, cell-free DNA manufacturing process eliminates bacterial backbone sequences and antibiotic resistance genes from the DNA starting material. In AAV production, 4basebio's hpDNA template has demonstrated comparable titers to plasmid DNA while requiring approximately 30% less DNA mass and transfection reagent, reducing material requirements and associated costs while supporting process efficiency and scalability. The cell-free manufacturing approach can also significantly shorten DNA production timelines compared with traditional plasmid manufacturing, helping developers to move more efficiently from sequence to viral vector production and toward the clinic. Christine Wolosin, Chief Commercial Officer at 4basebio, added: "This partnership reflects our commitment to pairing our proprietary DNA technology with partners who share our dedication to safety, quality, and reliability. Genezen's leadership in viral vector manufacturing, combined with the growing demand we're seeing from drug developers for our DNA molecules, speaks to where this industry is heading where synthetic DNA is becoming a critical enabler of genetic medicine. 4basebio is focused on giving drug developers a manufacturing platform upon which they can confidently build their clinical programs." Susan D'Costa, Chief Technical and Commercial Officer at Genezen, added: "As the cell and gene therapy field continues to mature, developers need manufacturing solutions that not only address today's challenges, but are designed with the needs of later-stage development in mind. 4basebio's approach to synthetic DNA represents an exciting advancement in the tools available to viral vector developers. By combining innovative technologies with deep process and manufacturing expertise, we have an opportunity to help developers build more efficient, scalable manufacturing strategies from the outset - and keep the focus where it belongs: advancing therapies for patients." About 4basebio 4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality. About Genezen Genezen is a best-in-class gene therapy CDMO with over 12 years of experience and state-of-the-art viral vector manufacturing facilities. From concept to commercial scale, Genezen partners with innovators to deliver life-saving gene and cell therapies worldwide. Learn more at genezen.com or follow Genezen on LinkedIn. Forward-looking statements This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different. SOURCE Genezen NOTE: This content is not written by or endorsed by "WOWK", its advertisers, or Nexstar Media Inc.

WOBN
Aug 3rd, 2026
Genezen and the Raiden Science Foundation announce partnership for AAV9 gene replacement therapy for UBA5 clinical trial.

Genezen and the Raiden Science Foundation announce partnership for AAV9 gene replacement therapy for UBA5 clinical trial. August 3, 2026 WOBN news, syndication comments off on Genezen and the Raiden Science Foundation announce partnership for AAV9 gene replacement therapy for UBA5 clinical trial. INDIANAPOLIS and BEAVERTON, Ore., Aug. 3, 2026 /PRNewswire/ - Genezen, a best-in-class gene therapy contract development and manufacturing organization (CDMO), and the Raiden Science Foundation (RSF), a parent-led rare disease organization, today announced a manufacturing partnership for...

Yahoo Finance
Nov 12th, 2025
Genezen Announces Manufacturing Partnership with Humane Genomics to Advance Oncolytic Virus Therapy for Pediatric Liver Cancer

Genezen announces manufacturing partnership with Humane Genomics to advance oncolytic virus therapy for pediatric liver cancer. INDIANAPOLIS and NEW YORK, Nov. 12, 2025 /PRNewswire/ - Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Humane Genomics, a biotechnology company developing oncolytic viral therapies, today announced a partnership for process transfer and cGMP manufacturing of HGI627, a novel therapy targeting pediatric liver cancer (hepatoblastoma). Humane Genomics uses its proprietary synthetic RNA virus platform to rapidly design and engineer RNA viruses with precise anti-cancer capabilities. Through a two-factor selectivity mechanism, these therapies infect and replicate only in targeted cancer cells, leaving healthy tissue unharmed. The company's platform powers a growing pipeline of next-generation viral therapies across multiple cancer types, including their lead candidate, HGI627. Under this collaboration, Genezen will perform technology transfer, process development, and cGMP manufacturing of the VSV-based HGI627 therapy. "Genezen is excited to partner with Humane Genomics on this novel cancer treatment and provide our best-in-class manufacturing expertise to bring this critical therapy to life for pediatric patients," said Steve Favaloro, chairman and chief executive officer of Genezen. "This partnership reinforces our commitment to supporting innovators at every stage of development and highlights the deep technical expertise and commitment to patients of the Genezen team." Peter Weijmarshausen, co-founder and chief executive officer of Humane Genomics, added, "We are thrilled to partner with Genezen. Their experienced, dynamic team and state-of-the-art facilities make them a perfect match to turn our groundbreaking science into real therapies for patients." About Genezen Genezen is a best-in-class gene therapy CDMO with over a decade of experience and state-of-the-art viral vector manufacturing facilities. From concept to commercial scale, Genezen partners with innovators to deliver life-saving gene and cell therapies worldwide. Learn more at genezen.com or follow Genezen on LinkedIn. About Humane Genomics Humane Genomics develops oncolytic viral therapies using a groundbreaking RNA virus platform designed to selectively target cancer cells. Learn more at humanegenomics.com or follow Humane Genomics on LinkedIn. View original content to download multimedia:https://www.prnewswire.com/news-releases/genezen-announces-manufacturing-partnership-with-humane-genomics-to-advance-oncolytic-virus-therapy-for-pediatric-liver-cancer-302612525.html

Genezen
Nov 7th, 2025
Genezen Partners with Charlotte & Gwenyth Gray Foundation on CLN6 Batten Disease

Genezen partners with Charlotte & Gwenyth Gray Foundation on CLN6 Batten Disease. Imagine a disease that robs you of your sight, your movement, and cognitively impairs you before it becomes fatal? Now imagine this happening to a child. This is often the reality of Batten's disease. The team at Genezen is honored to partner with the Charlotte & Gwenyth Gray Foundation, started by two parents committed to finding a cure for Batten Disease to save the lives of their daughters; the Foundation recognizes firsthand the day-to-day challenges of living with a rare disease. In addition to funding research, the Foundation also provides financial support to families for education, patient therapies, and equipment critical to their well-being and rehabilitation. While Genezen Inc. can't disclose the current project Genezen Inc. is working on together, Genezen Inc. look forward to sharing its progress in 2026. To learn more about Batten Disease and the work the foundation is doing, visit https://www.curebatten.org/education/

Genezen
Nov 3rd, 2025
Genezen Named a BioSpace 2026 Best Places to Work Winner

Genezen named a BioSpace 2026 Best Places to Work winner. Genezen Inc. is thrilled to announce that Genezen Inc. has been named a BioSpace 2026 Best Place to Work. As a best-in-class gene therapy CDMO, Genezen Inc. pride ourselves on its flexibility and scalability of its sites to work with innovators at every stage to deliver life-saving gene and cell therapies worldwide. With over a decade of experience and state-of-the-art viral vector manufacturing facilities, Genezen Inc. tailor its partnership-model approach to all sizes and stages of organizations, to make viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. But what truly sets Genezen Inc. apart is its world-class team. As problem solvers who appreciate other problem solvers, its existence and operations always point forward to scientific advancement as Genezen Inc. seek to connect good science with better cures. Skill and progress are developed through dedication and hard work. Genezen Inc. succeed in teams who are flexible and collaborative. Genezen Inc. is all solution architects - thriving in a rapidly changing environment - leveraging the power of viral vectors to contribute to the advancement of cutting-edge therapeutics. Partnership is its priority. Genezen Inc. tap into its superior service and technical expertise to help its clients create gene and cell therapy products of the highest quality. To achieve this, Genezen Inc. seek team members who not only have the technical expertise required, but also offer proactive, collaborative, and creative solutions to drive customer success. Together, Genezen Inc. is bringing therapies to life. And its recognition as a BioSpace 2026 Best Places to Work winner demonstrates that its people are proud of the work Genezen Inc. do together. BioSpace, the leading source for life sciences news and careers, includes 50 U.S. operating employers in its Best Places to Work list that have been recognized as the most sought-after in the industry by the life sciences community. Genezen is honored to have been included in the small employer category. "This award is incredibly meaningful to us, especially as it symbolizes how we truly live our patient-focused CURES values here at Genezen," said Steve Favaloro, Chairman and CEO. "The recognition also illustrates our positive reputation in the field and the value that we provide to our business partners. I am proud to be a part of this organization and to work alongside individuals who are passionate about making a difference continue to pursue innovation in this field. It's not easy work, but it's always fulfilling." This is BioSpace's fifth Best Places to Work list. The list demonstrates a company's desirability in the recruitment marketplace, based on the votes and ratings of thousands of life science community members. BioSpace considers each organization's merits with particular emphasis on culture, career growth and development opportunities, leadership and innovation. Genezen Inc. is proud of the culture Genezen Inc. has built together. Its CURES values - a commitment to science, acting with urgency for patients, and executing with excellence and integrity - ground Genezen Inc. and empower Genezen Inc. to grow stronger together. If you're someone who wants to promote scientific advancement while growing personally and professionally, you may be a perfect fit for Genezen. Browse its current openings here: https://www.genezen.com/careers/join-the-team/#jobopenings Its BioSpace Best Places to Work achievement is underscored by its recent Massachusetts Life Sciences Center (MLSC) award. Massachusetts Governor Maura Healey and the MLSC have announced more than $17 million in tax incentives to help create 800 new jobs across the state's thriving life sciences industry. Genezen Inc. is proud to share that Genezen was among the companies selected to receive an award. This grant will help Genezen Inc. continue investing in growth, innovation, and job creation in the life sciences space - driving forward its mission to advance cell and gene therapies through science-driven development and manufacturing solutions and make a lasting impact on patients. About Best Places to Work Nominations for Best Places to Work were open in June 2025. Voting was conducted in August 2025. BioSpace reviewed the votes and rankings submitted by over 7,500 life sciences professionals. Respondents were asked to identify their top three most desirable biopharma companies, segmented by large (more than 1,000+ employees) and small (less than 1,000 employees) organizations. Respondents were also asked to rate their top choice organization on attributes including compensation, innovation, career growth opportunities, leadership, culture, diversity, equity and inclusion, reputation, and flexibility and remote work. About BioSpace BioSpace is the hub for life science news and jobs. Genezen Inc. provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Learn more and subscribe at www.biospace.com